Global NSAIDs for Dysmenorrhea Market Growth 2025-2031
The report requires updating with new data and is sent in 48 hours after order is placed.
The global NSAIDs for Dysmenorrhea market size is predicted to grow from US$ 4419 million in 2025 to US$ 6057 million in 2031; it is expected to grow at a CAGR of 5.4% from 2025 to 2031.
Diclofenac, ibuprofen, ketoprofen, meclofenamate, mefenamic acid, and naproxen are the NSAIDs specifically approved by the US Food and Drug Administration (FDA) for treatment of dysmenorrhea.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “NSAIDs for Dysmenorrhea Industry Forecast” looks at past sales and reviews total world NSAIDs for Dysmenorrhea sales in 2024, providing a comprehensive analysis by region and market sector of projected NSAIDs for Dysmenorrhea sales for 2025 through 2031. With NSAIDs for Dysmenorrhea sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world NSAIDs for Dysmenorrhea industry.
This Insight Report provides a comprehensive analysis of the global NSAIDs for Dysmenorrhea landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on NSAIDs for Dysmenorrhea portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global NSAIDs for Dysmenorrhea market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for NSAIDs for Dysmenorrhea and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global NSAIDs for Dysmenorrhea.
This report presents a comprehensive overview, market shares, and growth opportunities of NSAIDs for Dysmenorrhea market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global NSAIDs for Dysmenorrhea market?
What factors are driving NSAIDs for Dysmenorrhea market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do NSAIDs for Dysmenorrhea market opportunities vary by end market size?
How does NSAIDs for Dysmenorrhea break out by Type, by Application?
The global NSAIDs for Dysmenorrhea market size is predicted to grow from US$ 4419 million in 2025 to US$ 6057 million in 2031; it is expected to grow at a CAGR of 5.4% from 2025 to 2031.
Diclofenac, ibuprofen, ketoprofen, meclofenamate, mefenamic acid, and naproxen are the NSAIDs specifically approved by the US Food and Drug Administration (FDA) for treatment of dysmenorrhea.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “NSAIDs for Dysmenorrhea Industry Forecast” looks at past sales and reviews total world NSAIDs for Dysmenorrhea sales in 2024, providing a comprehensive analysis by region and market sector of projected NSAIDs for Dysmenorrhea sales for 2025 through 2031. With NSAIDs for Dysmenorrhea sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world NSAIDs for Dysmenorrhea industry.
This Insight Report provides a comprehensive analysis of the global NSAIDs for Dysmenorrhea landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on NSAIDs for Dysmenorrhea portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global NSAIDs for Dysmenorrhea market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for NSAIDs for Dysmenorrhea and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global NSAIDs for Dysmenorrhea.
This report presents a comprehensive overview, market shares, and growth opportunities of NSAIDs for Dysmenorrhea market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Ibuprofen
- Celecoxib
- Ketoprofen
- Others
- Hospital
- Clinic
- Pharmacy
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- IOLCP
- Granules Biocause
- Strides Shasun
- BASF
- SI Group
- Hisoar
- Pfizer Inc
- Teva
- Mylan
- Apotex
- Lupin
- SANOFI-Aventis
- Boehringer-Ingelheim
- BEC Chemicals
- Shandong Xinhua Pharmaceutical
- Hengrui Medicine
- Hubei Biocause Heilen Pharmaceutical
- Zibo Xinhua-PERRIGO Pharmaceutical
- Zhejiang Jiuzhou
- Hubei Xunda
What is the 10-year outlook for the global NSAIDs for Dysmenorrhea market?
What factors are driving NSAIDs for Dysmenorrhea market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do NSAIDs for Dysmenorrhea market opportunities vary by end market size?
How does NSAIDs for Dysmenorrhea break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global NSAIDs for Dysmenorrhea Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for NSAIDs for Dysmenorrhea by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for NSAIDs for Dysmenorrhea by Country/Region, 2020, 2024 & 2031
2.2 NSAIDs for Dysmenorrhea Segment by Type
2.2.1 Ibuprofen
2.2.2 Celecoxib
2.2.3 Ketoprofen
2.2.4 Others
2.3 NSAIDs for Dysmenorrhea Sales by Type
2.3.1 Global NSAIDs for Dysmenorrhea Sales Market Share by Type (2020-2025)
2.3.2 Global NSAIDs for Dysmenorrhea Revenue and Market Share by Type (2020-2025)
2.3.3 Global NSAIDs for Dysmenorrhea Sale Price by Type (2020-2025)
2.4 NSAIDs for Dysmenorrhea Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Pharmacy
2.4.4 Other
2.5 NSAIDs for Dysmenorrhea Sales by Application
2.5.1 Global NSAIDs for Dysmenorrhea Sale Market Share by Application (2020-2025)
2.5.2 Global NSAIDs for Dysmenorrhea Revenue and Market Share by Application (2020-2025)
2.5.3 Global NSAIDs for Dysmenorrhea Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global NSAIDs for Dysmenorrhea Breakdown Data by Company
3.1.1 Global NSAIDs for Dysmenorrhea Annual Sales by Company (2020-2025)
3.1.2 Global NSAIDs for Dysmenorrhea Sales Market Share by Company (2020-2025)
3.2 Global NSAIDs for Dysmenorrhea Annual Revenue by Company (2020-2025)
3.2.1 Global NSAIDs for Dysmenorrhea Revenue by Company (2020-2025)
3.2.2 Global NSAIDs for Dysmenorrhea Revenue Market Share by Company (2020-2025)
3.3 Global NSAIDs for Dysmenorrhea Sale Price by Company
3.4 Key Manufacturers NSAIDs for Dysmenorrhea Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers NSAIDs for Dysmenorrhea Product Location Distribution
3.4.2 Players NSAIDs for Dysmenorrhea Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NSAIDS FOR DYSMENORRHEA BY GEOGRAPHIC REGION
4.1 World Historic NSAIDs for Dysmenorrhea Market Size by Geographic Region (2020-2025)
4.1.1 Global NSAIDs for Dysmenorrhea Annual Sales by Geographic Region (2020-2025)
4.1.2 Global NSAIDs for Dysmenorrhea Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic NSAIDs for Dysmenorrhea Market Size by Country/Region (2020-2025)
4.2.1 Global NSAIDs for Dysmenorrhea Annual Sales by Country/Region (2020-2025)
4.2.2 Global NSAIDs for Dysmenorrhea Annual Revenue by Country/Region (2020-2025)
4.3 Americas NSAIDs for Dysmenorrhea Sales Growth
4.4 APAC NSAIDs for Dysmenorrhea Sales Growth
4.5 Europe NSAIDs for Dysmenorrhea Sales Growth
4.6 Middle East & Africa NSAIDs for Dysmenorrhea Sales Growth
5 AMERICAS
5.1 Americas NSAIDs for Dysmenorrhea Sales by Country
5.1.1 Americas NSAIDs for Dysmenorrhea Sales by Country (2020-2025)
5.1.2 Americas NSAIDs for Dysmenorrhea Revenue by Country (2020-2025)
5.2 Americas NSAIDs for Dysmenorrhea Sales by Type (2020-2025)
5.3 Americas NSAIDs for Dysmenorrhea Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC NSAIDs for Dysmenorrhea Sales by Region
6.1.1 APAC NSAIDs for Dysmenorrhea Sales by Region (2020-2025)
6.1.2 APAC NSAIDs for Dysmenorrhea Revenue by Region (2020-2025)
6.2 APAC NSAIDs for Dysmenorrhea Sales by Type (2020-2025)
6.3 APAC NSAIDs for Dysmenorrhea Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe NSAIDs for Dysmenorrhea by Country
7.1.1 Europe NSAIDs for Dysmenorrhea Sales by Country (2020-2025)
7.1.2 Europe NSAIDs for Dysmenorrhea Revenue by Country (2020-2025)
7.2 Europe NSAIDs for Dysmenorrhea Sales by Type (2020-2025)
7.3 Europe NSAIDs for Dysmenorrhea Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa NSAIDs for Dysmenorrhea by Country
8.1.1 Middle East & Africa NSAIDs for Dysmenorrhea Sales by Country (2020-2025)
8.1.2 Middle East & Africa NSAIDs for Dysmenorrhea Revenue by Country (2020-2025)
8.2 Middle East & Africa NSAIDs for Dysmenorrhea Sales by Type (2020-2025)
8.3 Middle East & Africa NSAIDs for Dysmenorrhea Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of NSAIDs for Dysmenorrhea
10.3 Manufacturing Process Analysis of NSAIDs for Dysmenorrhea
10.4 Industry Chain Structure of NSAIDs for Dysmenorrhea
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 NSAIDs for Dysmenorrhea Distributors
11.3 NSAIDs for Dysmenorrhea Customer
12 WORLD FORECAST REVIEW FOR NSAIDS FOR DYSMENORRHEA BY GEOGRAPHIC REGION
12.1 Global NSAIDs for Dysmenorrhea Market Size Forecast by Region
12.1.1 Global NSAIDs for Dysmenorrhea Forecast by Region (2026-2031)
12.1.2 Global NSAIDs for Dysmenorrhea Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global NSAIDs for Dysmenorrhea Forecast by Type (2026-2031)
12.7 Global NSAIDs for Dysmenorrhea Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 IOLCP
13.1.1 IOLCP Company Information
13.1.2 IOLCP NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.1.3 IOLCP NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 IOLCP Main Business Overview
13.1.5 IOLCP Latest Developments
13.2 Granules Biocause
13.2.1 Granules Biocause Company Information
13.2.2 Granules Biocause NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.2.3 Granules Biocause NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Granules Biocause Main Business Overview
13.2.5 Granules Biocause Latest Developments
13.3 Strides Shasun
13.3.1 Strides Shasun Company Information
13.3.2 Strides Shasun NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.3.3 Strides Shasun NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Strides Shasun Main Business Overview
13.3.5 Strides Shasun Latest Developments
13.4 BASF
13.4.1 BASF Company Information
13.4.2 BASF NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.4.3 BASF NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 BASF Main Business Overview
13.4.5 BASF Latest Developments
13.5 SI Group
13.5.1 SI Group Company Information
13.5.2 SI Group NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.5.3 SI Group NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 SI Group Main Business Overview
13.5.5 SI Group Latest Developments
13.6 Hisoar
13.6.1 Hisoar Company Information
13.6.2 Hisoar NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.6.3 Hisoar NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Hisoar Main Business Overview
13.6.5 Hisoar Latest Developments
13.7 Pfizer Inc
13.7.1 Pfizer Inc Company Information
13.7.2 Pfizer Inc NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.7.3 Pfizer Inc NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Pfizer Inc Main Business Overview
13.7.5 Pfizer Inc Latest Developments
13.8 Teva
13.8.1 Teva Company Information
13.8.2 Teva NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.8.3 Teva NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Teva Main Business Overview
13.8.5 Teva Latest Developments
13.9 Mylan
13.9.1 Mylan Company Information
13.9.2 Mylan NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.9.3 Mylan NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Mylan Main Business Overview
13.9.5 Mylan Latest Developments
13.10 Apotex
13.10.1 Apotex Company Information
13.10.2 Apotex NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.10.3 Apotex NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Apotex Main Business Overview
13.10.5 Apotex Latest Developments
13.11 Lupin
13.11.1 Lupin Company Information
13.11.2 Lupin NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.11.3 Lupin NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Lupin Main Business Overview
13.11.5 Lupin Latest Developments
13.12 SANOFI-Aventis
13.12.1 SANOFI-Aventis Company Information
13.12.2 SANOFI-Aventis NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.12.3 SANOFI-Aventis NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 SANOFI-Aventis Main Business Overview
13.12.5 SANOFI-Aventis Latest Developments
13.13 Boehringer-Ingelheim
13.13.1 Boehringer-Ingelheim Company Information
13.13.2 Boehringer-Ingelheim NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.13.3 Boehringer-Ingelheim NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Boehringer-Ingelheim Main Business Overview
13.13.5 Boehringer-Ingelheim Latest Developments
13.14 BEC Chemicals
13.14.1 BEC Chemicals Company Information
13.14.2 BEC Chemicals NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.14.3 BEC Chemicals NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 BEC Chemicals Main Business Overview
13.14.5 BEC Chemicals Latest Developments
13.15 Shandong Xinhua Pharmaceutical
13.15.1 Shandong Xinhua Pharmaceutical Company Information
13.15.2 Shandong Xinhua Pharmaceutical NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.15.3 Shandong Xinhua Pharmaceutical NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Shandong Xinhua Pharmaceutical Main Business Overview
13.15.5 Shandong Xinhua Pharmaceutical Latest Developments
13.16 Hengrui Medicine
13.16.1 Hengrui Medicine Company Information
13.16.2 Hengrui Medicine NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.16.3 Hengrui Medicine NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Hengrui Medicine Main Business Overview
13.16.5 Hengrui Medicine Latest Developments
13.17 Hubei Biocause Heilen Pharmaceutical
13.17.1 Hubei Biocause Heilen Pharmaceutical Company Information
13.17.2 Hubei Biocause Heilen Pharmaceutical NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.17.3 Hubei Biocause Heilen Pharmaceutical NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Hubei Biocause Heilen Pharmaceutical Main Business Overview
13.17.5 Hubei Biocause Heilen Pharmaceutical Latest Developments
13.18 Zibo Xinhua-PERRIGO Pharmaceutical
13.18.1 Zibo Xinhua-PERRIGO Pharmaceutical Company Information
13.18.2 Zibo Xinhua-PERRIGO Pharmaceutical NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.18.3 Zibo Xinhua-PERRIGO Pharmaceutical NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 Zibo Xinhua-PERRIGO Pharmaceutical Main Business Overview
13.18.5 Zibo Xinhua-PERRIGO Pharmaceutical Latest Developments
13.19 Zhejiang Jiuzhou
13.19.1 Zhejiang Jiuzhou Company Information
13.19.2 Zhejiang Jiuzhou NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.19.3 Zhejiang Jiuzhou NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.19.4 Zhejiang Jiuzhou Main Business Overview
13.19.5 Zhejiang Jiuzhou Latest Developments
13.20 Hubei Xunda
13.20.1 Hubei Xunda Company Information
13.20.2 Hubei Xunda NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.20.3 Hubei Xunda NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.20.4 Hubei Xunda Main Business Overview
13.20.5 Hubei Xunda Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. NSAIDs for Dysmenorrhea Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. NSAIDs for Dysmenorrhea Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Ibuprofen
Table 4. Major Players of Celecoxib
Table 5. Major Players of Ketoprofen
Table 6. Major Players of Others
Table 7. Global NSAIDs for Dysmenorrhea Sales byType (2020-2025) & (K Units)
Table 8. Global NSAIDs for Dysmenorrhea Sales Market Share byType (2020-2025)
Table 9. Global NSAIDs for Dysmenorrhea Revenue byType (2020-2025) & ($ million)
Table 10. Global NSAIDs for Dysmenorrhea Revenue Market Share byType (2020-2025)
Table 11. Global NSAIDs for Dysmenorrhea Sale Price byType (2020-2025) & (US$/Unit)
Table 12. Global NSAIDs for Dysmenorrhea Sale by Application (2020-2025) & (K Units)
Table 13. Global NSAIDs for Dysmenorrhea Sale Market Share by Application (2020-2025)
Table 14. Global NSAIDs for Dysmenorrhea Revenue by Application (2020-2025) & ($ million)
Table 15. Global NSAIDs for Dysmenorrhea Revenue Market Share by Application (2020-2025)
Table 16. Global NSAIDs for Dysmenorrhea Sale Price by Application (2020-2025) & (US$/Unit)
Table 17. Global NSAIDs for Dysmenorrhea Sales by Company (2020-2025) & (K Units)
Table 18. Global NSAIDs for Dysmenorrhea Sales Market Share by Company (2020-2025)
Table 19. Global NSAIDs for Dysmenorrhea Revenue by Company (2020-2025) & ($ millions)
Table 20. Global NSAIDs for Dysmenorrhea Revenue Market Share by Company (2020-2025)
Table 21. Global NSAIDs for Dysmenorrhea Sale Price by Company (2020-2025) & (US$/Unit)
Table 22. Key Manufacturers NSAIDs for Dysmenorrhea Producing Area Distribution and Sales Area
Table 23. Players NSAIDs for Dysmenorrhea Products Offered
Table 24. NSAIDs for Dysmenorrhea Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global NSAIDs for Dysmenorrhea Sales by Geographic Region (2020-2025) & (K Units)
Table 28. Global NSAIDs for Dysmenorrhea Sales Market Share Geographic Region (2020-2025)
Table 29. Global NSAIDs for Dysmenorrhea Revenue by Geographic Region (2020-2025) & ($ millions)
Table 30. Global NSAIDs for Dysmenorrhea Revenue Market Share by Geographic Region (2020-2025)
Table 31. Global NSAIDs for Dysmenorrhea Sales by Country/Region (2020-2025) & (K Units)
Table 32. Global NSAIDs for Dysmenorrhea Sales Market Share by Country/Region (2020-2025)
Table 33. Global NSAIDs for Dysmenorrhea Revenue by Country/Region (2020-2025) & ($ millions)
Table 34. Global NSAIDs for Dysmenorrhea Revenue Market Share by Country/Region (2020-2025)
Table 35. Americas NSAIDs for Dysmenorrhea Sales by Country (2020-2025) & (K Units)
Table 36. Americas NSAIDs for Dysmenorrhea Sales Market Share by Country (2020-2025)
Table 37. Americas NSAIDs for Dysmenorrhea Revenue by Country (2020-2025) & ($ millions)
Table 38. Americas NSAIDs for Dysmenorrhea Sales byType (2020-2025) & (K Units)
Table 39. Americas NSAIDs for Dysmenorrhea Sales by Application (2020-2025) & (K Units)
Table 40. APAC NSAIDs for Dysmenorrhea Sales by Region (2020-2025) & (K Units)
Table 41. APAC NSAIDs for Dysmenorrhea Sales Market Share by Region (2020-2025)
Table 42. APAC NSAIDs for Dysmenorrhea Revenue by Region (2020-2025) & ($ millions)
Table 43. APAC NSAIDs for Dysmenorrhea Sales byType (2020-2025) & (K Units)
Table 44. APAC NSAIDs for Dysmenorrhea Sales by Application (2020-2025) & (K Units)
Table 45. Europe NSAIDs for Dysmenorrhea Sales by Country (2020-2025) & (K Units)
Table 46. Europe NSAIDs for Dysmenorrhea Revenue by Country (2020-2025) & ($ millions)
Table 47. Europe NSAIDs for Dysmenorrhea Sales byType (2020-2025) & (K Units)
Table 48. Europe NSAIDs for Dysmenorrhea Sales by Application (2020-2025) & (K Units)
Table 49. Middle East & Africa NSAIDs for Dysmenorrhea Sales by Country (2020-2025) & (K Units)
Table 50. Middle East & Africa NSAIDs for Dysmenorrhea Revenue Market Share by Country (2020-2025)
Table 51. Middle East & Africa NSAIDs for Dysmenorrhea Sales byType (2020-2025) & (K Units)
Table 52. Middle East & Africa NSAIDs for Dysmenorrhea Sales by Application (2020-2025) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of NSAIDs for Dysmenorrhea
Table 54. Key Market Challenges & Risks of NSAIDs for Dysmenorrhea
Table 55. Key IndustryTrends of NSAIDs for Dysmenorrhea
Table 56. NSAIDs for Dysmenorrhea Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. NSAIDs for Dysmenorrhea Distributors List
Table 59. NSAIDs for Dysmenorrhea Customer List
Table 60. Global NSAIDs for Dysmenorrhea SalesForecast by Region (2026-2031) & (K Units)
Table 61. Global NSAIDs for Dysmenorrhea RevenueForecast by Region (2026-2031) & ($ millions)
Table 62. Americas NSAIDs for Dysmenorrhea SalesForecast by Country (2026-2031) & (K Units)
Table 63. Americas NSAIDs for Dysmenorrhea Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 64. APAC NSAIDs for Dysmenorrhea SalesForecast by Region (2026-2031) & (K Units)
Table 65. APAC NSAIDs for Dysmenorrhea Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 66. Europe NSAIDs for Dysmenorrhea SalesForecast by Country (2026-2031) & (K Units)
Table 67. Europe NSAIDs for Dysmenorrhea RevenueForecast by Country (2026-2031) & ($ millions)
Table 68. Middle East & Africa NSAIDs for Dysmenorrhea SalesForecast by Country (2026-2031) & (K Units)
Table 69. Middle East & Africa NSAIDs for Dysmenorrhea RevenueForecast by Country (2026-2031) & ($ millions)
Table 70. Global NSAIDs for Dysmenorrhea SalesForecast byType (2026-2031) & (K Units)
Table 71. Global NSAIDs for Dysmenorrhea RevenueForecast byType (2026-2031) & ($ millions)
Table 72. Global NSAIDs for Dysmenorrhea SalesForecast by Application (2026-2031) & (K Units)
Table 73. Global NSAIDs for Dysmenorrhea RevenueForecast by Application (2026-2031) & ($ millions)
Table 74. IOLCP Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 75. IOLCP NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 76. IOLCP NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 77. IOLCP Main Business
Table 78. IOLCP Latest Developments
Table 79. Granules Biocause Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 80. Granules Biocause NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 81. Granules Biocause NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 82. Granules Biocause Main Business
Table 83. Granules Biocause Latest Developments
Table 84. Strides Shasun Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 85. Strides Shasun NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 86. Strides Shasun NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 87. Strides Shasun Main Business
Table 88. Strides Shasun Latest Developments
Table 89. BASF Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 90. BASF NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 91. BASF NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 92. BASF Main Business
Table 93. BASF Latest Developments
Table 94. SI Group Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 95. SI Group NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 96. SI Group NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 97. SI Group Main Business
Table 98. SI Group Latest Developments
Table 99. Hisoar Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 100. Hisoar NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 101. Hisoar NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 102. Hisoar Main Business
Table 103. Hisoar Latest Developments
Table 104. Pfizer Inc Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 105. Pfizer Inc NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 106. Pfizer Inc NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 107. Pfizer Inc Main Business
Table 108. Pfizer Inc Latest Developments
Table 109.Teva Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 110.Teva NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 111.Teva NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 112.Teva Main Business
Table 113.Teva Latest Developments
Table 114. Mylan Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 115. Mylan NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 116. Mylan NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 117. Mylan Main Business
Table 118. Mylan Latest Developments
Table 119. Apotex Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 120. Apotex NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 121. Apotex NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 122. Apotex Main Business
Table 123. Apotex Latest Developments
Table 124. Lupin Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 125. Lupin NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 126. Lupin NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 127. Lupin Main Business
Table 128. Lupin Latest Developments
Table 129. SANOFI-Aventis Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 130. SANOFI-Aventis NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 131. SANOFI-Aventis NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 132. SANOFI-Aventis Main Business
Table 133. SANOFI-Aventis Latest Developments
Table 134. Boehringer-Ingelheim Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 135. Boehringer-Ingelheim NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 136. Boehringer-Ingelheim NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 137. Boehringer-Ingelheim Main Business
Table 138. Boehringer-Ingelheim Latest Developments
Table 139. BEC Chemicals Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 140. BEC Chemicals NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 141. BEC Chemicals NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 142. BEC Chemicals Main Business
Table 143. BEC Chemicals Latest Developments
Table 144. Shandong Xinhua Pharmaceutical Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 145. Shandong Xinhua Pharmaceutical NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 146. Shandong Xinhua Pharmaceutical NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 147. Shandong Xinhua Pharmaceutical Main Business
Table 148. Shandong Xinhua Pharmaceutical Latest Developments
Table 149. Hengrui Medicine Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 150. Hengrui Medicine NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 151. Hengrui Medicine NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 152. Hengrui Medicine Main Business
Table 153. Hengrui Medicine Latest Developments
Table 154. Hubei Biocause Heilen Pharmaceutical Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 155. Hubei Biocause Heilen Pharmaceutical NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 156. Hubei Biocause Heilen Pharmaceutical NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 157. Hubei Biocause Heilen Pharmaceutical Main Business
Table 158. Hubei Biocause Heilen Pharmaceutical Latest Developments
Table 159. Zibo Xinhua-PERRIGO Pharmaceutical Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 160. Zibo Xinhua-PERRIGO Pharmaceutical NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 161. Zibo Xinhua-PERRIGO Pharmaceutical NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 162. Zibo Xinhua-PERRIGO Pharmaceutical Main Business
Table 163. Zibo Xinhua-PERRIGO Pharmaceutical Latest Developments
Table 164. Zhejiang Jiuzhou Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 165. Zhejiang Jiuzhou NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 166. Zhejiang Jiuzhou NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 167. Zhejiang Jiuzhou Main Business
Table 168. Zhejiang Jiuzhou Latest Developments
Table 169. Hubei Xunda Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 170. Hubei Xunda NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 171. Hubei Xunda NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 172. Hubei Xunda Main Business
Table 173. Hubei Xunda Latest Developments
LIST OFFIGURES
Figure 1. Picture of NSAIDs for Dysmenorrhea
Figure 2. NSAIDs for Dysmenorrhea Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global NSAIDs for Dysmenorrhea Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global NSAIDs for Dysmenorrhea Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. NSAIDs for Dysmenorrhea Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. NSAIDs for Dysmenorrhea Sales Market Share by Country/Region (2024)
Figure 10. NSAIDs for Dysmenorrhea Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Ibuprofen
Figure 12. Product Picture of Celecoxib
Figure 13. Product Picture of Ketoprofen
Figure 14. Product Picture of Others
Figure 15. Global NSAIDs for Dysmenorrhea Sales Market Share byType in 2025
Figure 16. Global NSAIDs for Dysmenorrhea Revenue Market Share byType (2020-2025)
Figure 17. NSAIDs for Dysmenorrhea Consumed in Hospital
Figure 18. Global NSAIDs for Dysmenorrhea Market: Hospital (2020-2025) & (K Units)
Figure 19. NSAIDs for Dysmenorrhea Consumed in Clinic
Figure 20. Global NSAIDs for Dysmenorrhea Market: Clinic (2020-2025) & (K Units)
Figure 21. NSAIDs for Dysmenorrhea Consumed in Pharmacy
Figure 22. Global NSAIDs for Dysmenorrhea Market: Pharmacy (2020-2025) & (K Units)
Figure 23. NSAIDs for Dysmenorrhea Consumed in Other
Figure 24. Global NSAIDs for Dysmenorrhea Market: Other (2020-2025) & (K Units)
Figure 25. Global NSAIDs for Dysmenorrhea Sale Market Share by Application (2024)
Figure 26. Global NSAIDs for Dysmenorrhea Revenue Market Share by Application in 2025
Figure 27. NSAIDs for Dysmenorrhea Sales by Company in 2025 (K Units)
Figure 28. Global NSAIDs for Dysmenorrhea Sales Market Share by Company in 2025
Figure 29. NSAIDs for Dysmenorrhea Revenue by Company in 2025 ($ millions)
Figure 30. Global NSAIDs for Dysmenorrhea Revenue Market Share by Company in 2025
Figure 31. Global NSAIDs for Dysmenorrhea Sales Market Share by Geographic Region (2020-2025)
Figure 32. Global NSAIDs for Dysmenorrhea Revenue Market Share by Geographic Region in 2025
Figure 33. Americas NSAIDs for Dysmenorrhea Sales 2020-2025 (K Units)
Figure 34. Americas NSAIDs for Dysmenorrhea Revenue 2020-2025 ($ millions)
Figure 35. APAC NSAIDs for Dysmenorrhea Sales 2020-2025 (K Units)
Figure 36. APAC NSAIDs for Dysmenorrhea Revenue 2020-2025 ($ millions)
Figure 37. Europe NSAIDs for Dysmenorrhea Sales 2020-2025 (K Units)
Figure 38. Europe NSAIDs for Dysmenorrhea Revenue 2020-2025 ($ millions)
Figure 39. Middle East & Africa NSAIDs for Dysmenorrhea Sales 2020-2025 (K Units)
Figure 40. Middle East & Africa NSAIDs for Dysmenorrhea Revenue 2020-2025 ($ millions)
Figure 41. Americas NSAIDs for Dysmenorrhea Sales Market Share by Country in 2025
Figure 42. Americas NSAIDs for Dysmenorrhea Revenue Market Share by Country (2020-2025)
Figure 43. Americas NSAIDs for Dysmenorrhea Sales Market Share byType (2020-2025)
Figure 44. Americas NSAIDs for Dysmenorrhea Sales Market Share by Application (2020-2025)
Figure 45. United States NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 46. Canada NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 47. Mexico NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 48. Brazil NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 49. APAC NSAIDs for Dysmenorrhea Sales Market Share by Region in 2025
Figure 50. APAC NSAIDs for Dysmenorrhea Revenue Market Share by Region (2020-2025)
Figure 51. APAC NSAIDs for Dysmenorrhea Sales Market Share byType (2020-2025)
Figure 52. APAC NSAIDs for Dysmenorrhea Sales Market Share by Application (2020-2025)
Figure 53. China NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 54. Japan NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 55. South Korea NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 56. Southeast Asia NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 57. India NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 58. Australia NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 59. ChinaTaiwan NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 60. Europe NSAIDs for Dysmenorrhea Sales Market Share by Country in 2025
Figure 61. Europe NSAIDs for Dysmenorrhea Revenue Market Share by Country (2020-2025)
Figure 62. Europe NSAIDs for Dysmenorrhea Sales Market Share byType (2020-2025)
Figure 63. Europe NSAIDs for Dysmenorrhea Sales Market Share by Application (2020-2025)
Figure 64. Germany NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 65.France NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 66. UK NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 67. Italy NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 68. Russia NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 69. Middle East & Africa NSAIDs for Dysmenorrhea Sales Market Share by Country (2020-2025)
Figure 70. Middle East & Africa NSAIDs for Dysmenorrhea Sales Market Share byType (2020-2025)
Figure 71. Middle East & Africa NSAIDs for Dysmenorrhea Sales Market Share by Application (2020-2025)
Figure 72. Egypt NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 73. South Africa NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 74. Israel NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 75.Turkey NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 76. GCC Countries NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of NSAIDs for Dysmenorrhea in 2025
Figure 78. Manufacturing Process Analysis of NSAIDs for Dysmenorrhea
Figure 79. Industry Chain Structure of NSAIDs for Dysmenorrhea
Figure 80. Channels of Distribution
Figure 81. Global NSAIDs for Dysmenorrhea Sales MarketForecast by Region (2026-2031)
Figure 82. Global NSAIDs for Dysmenorrhea Revenue Market ShareForecast by Region (2026-2031)
Figure 83. Global NSAIDs for Dysmenorrhea Sales Market ShareForecast byType (2026-2031)
Figure 84. Global NSAIDs for Dysmenorrhea Revenue Market ShareForecast byType (2026-2031)
Figure 85. Global NSAIDs for Dysmenorrhea Sales Market ShareForecast by Application (2026-2031)
Figure 86. Global NSAIDs for Dysmenorrhea Revenue Market ShareForecast by Application (2026-2031)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global NSAIDs for Dysmenorrhea Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for NSAIDs for Dysmenorrhea by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for NSAIDs for Dysmenorrhea by Country/Region, 2020, 2024 & 2031
2.2 NSAIDs for Dysmenorrhea Segment by Type
2.2.1 Ibuprofen
2.2.2 Celecoxib
2.2.3 Ketoprofen
2.2.4 Others
2.3 NSAIDs for Dysmenorrhea Sales by Type
2.3.1 Global NSAIDs for Dysmenorrhea Sales Market Share by Type (2020-2025)
2.3.2 Global NSAIDs for Dysmenorrhea Revenue and Market Share by Type (2020-2025)
2.3.3 Global NSAIDs for Dysmenorrhea Sale Price by Type (2020-2025)
2.4 NSAIDs for Dysmenorrhea Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Pharmacy
2.4.4 Other
2.5 NSAIDs for Dysmenorrhea Sales by Application
2.5.1 Global NSAIDs for Dysmenorrhea Sale Market Share by Application (2020-2025)
2.5.2 Global NSAIDs for Dysmenorrhea Revenue and Market Share by Application (2020-2025)
2.5.3 Global NSAIDs for Dysmenorrhea Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global NSAIDs for Dysmenorrhea Breakdown Data by Company
3.1.1 Global NSAIDs for Dysmenorrhea Annual Sales by Company (2020-2025)
3.1.2 Global NSAIDs for Dysmenorrhea Sales Market Share by Company (2020-2025)
3.2 Global NSAIDs for Dysmenorrhea Annual Revenue by Company (2020-2025)
3.2.1 Global NSAIDs for Dysmenorrhea Revenue by Company (2020-2025)
3.2.2 Global NSAIDs for Dysmenorrhea Revenue Market Share by Company (2020-2025)
3.3 Global NSAIDs for Dysmenorrhea Sale Price by Company
3.4 Key Manufacturers NSAIDs for Dysmenorrhea Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers NSAIDs for Dysmenorrhea Product Location Distribution
3.4.2 Players NSAIDs for Dysmenorrhea Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NSAIDS FOR DYSMENORRHEA BY GEOGRAPHIC REGION
4.1 World Historic NSAIDs for Dysmenorrhea Market Size by Geographic Region (2020-2025)
4.1.1 Global NSAIDs for Dysmenorrhea Annual Sales by Geographic Region (2020-2025)
4.1.2 Global NSAIDs for Dysmenorrhea Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic NSAIDs for Dysmenorrhea Market Size by Country/Region (2020-2025)
4.2.1 Global NSAIDs for Dysmenorrhea Annual Sales by Country/Region (2020-2025)
4.2.2 Global NSAIDs for Dysmenorrhea Annual Revenue by Country/Region (2020-2025)
4.3 Americas NSAIDs for Dysmenorrhea Sales Growth
4.4 APAC NSAIDs for Dysmenorrhea Sales Growth
4.5 Europe NSAIDs for Dysmenorrhea Sales Growth
4.6 Middle East & Africa NSAIDs for Dysmenorrhea Sales Growth
5 AMERICAS
5.1 Americas NSAIDs for Dysmenorrhea Sales by Country
5.1.1 Americas NSAIDs for Dysmenorrhea Sales by Country (2020-2025)
5.1.2 Americas NSAIDs for Dysmenorrhea Revenue by Country (2020-2025)
5.2 Americas NSAIDs for Dysmenorrhea Sales by Type (2020-2025)
5.3 Americas NSAIDs for Dysmenorrhea Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC NSAIDs for Dysmenorrhea Sales by Region
6.1.1 APAC NSAIDs for Dysmenorrhea Sales by Region (2020-2025)
6.1.2 APAC NSAIDs for Dysmenorrhea Revenue by Region (2020-2025)
6.2 APAC NSAIDs for Dysmenorrhea Sales by Type (2020-2025)
6.3 APAC NSAIDs for Dysmenorrhea Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe NSAIDs for Dysmenorrhea by Country
7.1.1 Europe NSAIDs for Dysmenorrhea Sales by Country (2020-2025)
7.1.2 Europe NSAIDs for Dysmenorrhea Revenue by Country (2020-2025)
7.2 Europe NSAIDs for Dysmenorrhea Sales by Type (2020-2025)
7.3 Europe NSAIDs for Dysmenorrhea Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa NSAIDs for Dysmenorrhea by Country
8.1.1 Middle East & Africa NSAIDs for Dysmenorrhea Sales by Country (2020-2025)
8.1.2 Middle East & Africa NSAIDs for Dysmenorrhea Revenue by Country (2020-2025)
8.2 Middle East & Africa NSAIDs for Dysmenorrhea Sales by Type (2020-2025)
8.3 Middle East & Africa NSAIDs for Dysmenorrhea Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of NSAIDs for Dysmenorrhea
10.3 Manufacturing Process Analysis of NSAIDs for Dysmenorrhea
10.4 Industry Chain Structure of NSAIDs for Dysmenorrhea
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 NSAIDs for Dysmenorrhea Distributors
11.3 NSAIDs for Dysmenorrhea Customer
12 WORLD FORECAST REVIEW FOR NSAIDS FOR DYSMENORRHEA BY GEOGRAPHIC REGION
12.1 Global NSAIDs for Dysmenorrhea Market Size Forecast by Region
12.1.1 Global NSAIDs for Dysmenorrhea Forecast by Region (2026-2031)
12.1.2 Global NSAIDs for Dysmenorrhea Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global NSAIDs for Dysmenorrhea Forecast by Type (2026-2031)
12.7 Global NSAIDs for Dysmenorrhea Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 IOLCP
13.1.1 IOLCP Company Information
13.1.2 IOLCP NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.1.3 IOLCP NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 IOLCP Main Business Overview
13.1.5 IOLCP Latest Developments
13.2 Granules Biocause
13.2.1 Granules Biocause Company Information
13.2.2 Granules Biocause NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.2.3 Granules Biocause NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Granules Biocause Main Business Overview
13.2.5 Granules Biocause Latest Developments
13.3 Strides Shasun
13.3.1 Strides Shasun Company Information
13.3.2 Strides Shasun NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.3.3 Strides Shasun NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Strides Shasun Main Business Overview
13.3.5 Strides Shasun Latest Developments
13.4 BASF
13.4.1 BASF Company Information
13.4.2 BASF NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.4.3 BASF NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 BASF Main Business Overview
13.4.5 BASF Latest Developments
13.5 SI Group
13.5.1 SI Group Company Information
13.5.2 SI Group NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.5.3 SI Group NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 SI Group Main Business Overview
13.5.5 SI Group Latest Developments
13.6 Hisoar
13.6.1 Hisoar Company Information
13.6.2 Hisoar NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.6.3 Hisoar NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Hisoar Main Business Overview
13.6.5 Hisoar Latest Developments
13.7 Pfizer Inc
13.7.1 Pfizer Inc Company Information
13.7.2 Pfizer Inc NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.7.3 Pfizer Inc NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Pfizer Inc Main Business Overview
13.7.5 Pfizer Inc Latest Developments
13.8 Teva
13.8.1 Teva Company Information
13.8.2 Teva NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.8.3 Teva NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Teva Main Business Overview
13.8.5 Teva Latest Developments
13.9 Mylan
13.9.1 Mylan Company Information
13.9.2 Mylan NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.9.3 Mylan NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Mylan Main Business Overview
13.9.5 Mylan Latest Developments
13.10 Apotex
13.10.1 Apotex Company Information
13.10.2 Apotex NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.10.3 Apotex NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Apotex Main Business Overview
13.10.5 Apotex Latest Developments
13.11 Lupin
13.11.1 Lupin Company Information
13.11.2 Lupin NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.11.3 Lupin NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Lupin Main Business Overview
13.11.5 Lupin Latest Developments
13.12 SANOFI-Aventis
13.12.1 SANOFI-Aventis Company Information
13.12.2 SANOFI-Aventis NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.12.3 SANOFI-Aventis NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 SANOFI-Aventis Main Business Overview
13.12.5 SANOFI-Aventis Latest Developments
13.13 Boehringer-Ingelheim
13.13.1 Boehringer-Ingelheim Company Information
13.13.2 Boehringer-Ingelheim NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.13.3 Boehringer-Ingelheim NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Boehringer-Ingelheim Main Business Overview
13.13.5 Boehringer-Ingelheim Latest Developments
13.14 BEC Chemicals
13.14.1 BEC Chemicals Company Information
13.14.2 BEC Chemicals NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.14.3 BEC Chemicals NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 BEC Chemicals Main Business Overview
13.14.5 BEC Chemicals Latest Developments
13.15 Shandong Xinhua Pharmaceutical
13.15.1 Shandong Xinhua Pharmaceutical Company Information
13.15.2 Shandong Xinhua Pharmaceutical NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.15.3 Shandong Xinhua Pharmaceutical NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Shandong Xinhua Pharmaceutical Main Business Overview
13.15.5 Shandong Xinhua Pharmaceutical Latest Developments
13.16 Hengrui Medicine
13.16.1 Hengrui Medicine Company Information
13.16.2 Hengrui Medicine NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.16.3 Hengrui Medicine NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Hengrui Medicine Main Business Overview
13.16.5 Hengrui Medicine Latest Developments
13.17 Hubei Biocause Heilen Pharmaceutical
13.17.1 Hubei Biocause Heilen Pharmaceutical Company Information
13.17.2 Hubei Biocause Heilen Pharmaceutical NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.17.3 Hubei Biocause Heilen Pharmaceutical NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Hubei Biocause Heilen Pharmaceutical Main Business Overview
13.17.5 Hubei Biocause Heilen Pharmaceutical Latest Developments
13.18 Zibo Xinhua-PERRIGO Pharmaceutical
13.18.1 Zibo Xinhua-PERRIGO Pharmaceutical Company Information
13.18.2 Zibo Xinhua-PERRIGO Pharmaceutical NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.18.3 Zibo Xinhua-PERRIGO Pharmaceutical NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 Zibo Xinhua-PERRIGO Pharmaceutical Main Business Overview
13.18.5 Zibo Xinhua-PERRIGO Pharmaceutical Latest Developments
13.19 Zhejiang Jiuzhou
13.19.1 Zhejiang Jiuzhou Company Information
13.19.2 Zhejiang Jiuzhou NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.19.3 Zhejiang Jiuzhou NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.19.4 Zhejiang Jiuzhou Main Business Overview
13.19.5 Zhejiang Jiuzhou Latest Developments
13.20 Hubei Xunda
13.20.1 Hubei Xunda Company Information
13.20.2 Hubei Xunda NSAIDs for Dysmenorrhea Product Portfolios and Specifications
13.20.3 Hubei Xunda NSAIDs for Dysmenorrhea Sales, Revenue, Price and Gross Margin (2020-2025)
13.20.4 Hubei Xunda Main Business Overview
13.20.5 Hubei Xunda Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. NSAIDs for Dysmenorrhea Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. NSAIDs for Dysmenorrhea Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Ibuprofen
Table 4. Major Players of Celecoxib
Table 5. Major Players of Ketoprofen
Table 6. Major Players of Others
Table 7. Global NSAIDs for Dysmenorrhea Sales byType (2020-2025) & (K Units)
Table 8. Global NSAIDs for Dysmenorrhea Sales Market Share byType (2020-2025)
Table 9. Global NSAIDs for Dysmenorrhea Revenue byType (2020-2025) & ($ million)
Table 10. Global NSAIDs for Dysmenorrhea Revenue Market Share byType (2020-2025)
Table 11. Global NSAIDs for Dysmenorrhea Sale Price byType (2020-2025) & (US$/Unit)
Table 12. Global NSAIDs for Dysmenorrhea Sale by Application (2020-2025) & (K Units)
Table 13. Global NSAIDs for Dysmenorrhea Sale Market Share by Application (2020-2025)
Table 14. Global NSAIDs for Dysmenorrhea Revenue by Application (2020-2025) & ($ million)
Table 15. Global NSAIDs for Dysmenorrhea Revenue Market Share by Application (2020-2025)
Table 16. Global NSAIDs for Dysmenorrhea Sale Price by Application (2020-2025) & (US$/Unit)
Table 17. Global NSAIDs for Dysmenorrhea Sales by Company (2020-2025) & (K Units)
Table 18. Global NSAIDs for Dysmenorrhea Sales Market Share by Company (2020-2025)
Table 19. Global NSAIDs for Dysmenorrhea Revenue by Company (2020-2025) & ($ millions)
Table 20. Global NSAIDs for Dysmenorrhea Revenue Market Share by Company (2020-2025)
Table 21. Global NSAIDs for Dysmenorrhea Sale Price by Company (2020-2025) & (US$/Unit)
Table 22. Key Manufacturers NSAIDs for Dysmenorrhea Producing Area Distribution and Sales Area
Table 23. Players NSAIDs for Dysmenorrhea Products Offered
Table 24. NSAIDs for Dysmenorrhea Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global NSAIDs for Dysmenorrhea Sales by Geographic Region (2020-2025) & (K Units)
Table 28. Global NSAIDs for Dysmenorrhea Sales Market Share Geographic Region (2020-2025)
Table 29. Global NSAIDs for Dysmenorrhea Revenue by Geographic Region (2020-2025) & ($ millions)
Table 30. Global NSAIDs for Dysmenorrhea Revenue Market Share by Geographic Region (2020-2025)
Table 31. Global NSAIDs for Dysmenorrhea Sales by Country/Region (2020-2025) & (K Units)
Table 32. Global NSAIDs for Dysmenorrhea Sales Market Share by Country/Region (2020-2025)
Table 33. Global NSAIDs for Dysmenorrhea Revenue by Country/Region (2020-2025) & ($ millions)
Table 34. Global NSAIDs for Dysmenorrhea Revenue Market Share by Country/Region (2020-2025)
Table 35. Americas NSAIDs for Dysmenorrhea Sales by Country (2020-2025) & (K Units)
Table 36. Americas NSAIDs for Dysmenorrhea Sales Market Share by Country (2020-2025)
Table 37. Americas NSAIDs for Dysmenorrhea Revenue by Country (2020-2025) & ($ millions)
Table 38. Americas NSAIDs for Dysmenorrhea Sales byType (2020-2025) & (K Units)
Table 39. Americas NSAIDs for Dysmenorrhea Sales by Application (2020-2025) & (K Units)
Table 40. APAC NSAIDs for Dysmenorrhea Sales by Region (2020-2025) & (K Units)
Table 41. APAC NSAIDs for Dysmenorrhea Sales Market Share by Region (2020-2025)
Table 42. APAC NSAIDs for Dysmenorrhea Revenue by Region (2020-2025) & ($ millions)
Table 43. APAC NSAIDs for Dysmenorrhea Sales byType (2020-2025) & (K Units)
Table 44. APAC NSAIDs for Dysmenorrhea Sales by Application (2020-2025) & (K Units)
Table 45. Europe NSAIDs for Dysmenorrhea Sales by Country (2020-2025) & (K Units)
Table 46. Europe NSAIDs for Dysmenorrhea Revenue by Country (2020-2025) & ($ millions)
Table 47. Europe NSAIDs for Dysmenorrhea Sales byType (2020-2025) & (K Units)
Table 48. Europe NSAIDs for Dysmenorrhea Sales by Application (2020-2025) & (K Units)
Table 49. Middle East & Africa NSAIDs for Dysmenorrhea Sales by Country (2020-2025) & (K Units)
Table 50. Middle East & Africa NSAIDs for Dysmenorrhea Revenue Market Share by Country (2020-2025)
Table 51. Middle East & Africa NSAIDs for Dysmenorrhea Sales byType (2020-2025) & (K Units)
Table 52. Middle East & Africa NSAIDs for Dysmenorrhea Sales by Application (2020-2025) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of NSAIDs for Dysmenorrhea
Table 54. Key Market Challenges & Risks of NSAIDs for Dysmenorrhea
Table 55. Key IndustryTrends of NSAIDs for Dysmenorrhea
Table 56. NSAIDs for Dysmenorrhea Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. NSAIDs for Dysmenorrhea Distributors List
Table 59. NSAIDs for Dysmenorrhea Customer List
Table 60. Global NSAIDs for Dysmenorrhea SalesForecast by Region (2026-2031) & (K Units)
Table 61. Global NSAIDs for Dysmenorrhea RevenueForecast by Region (2026-2031) & ($ millions)
Table 62. Americas NSAIDs for Dysmenorrhea SalesForecast by Country (2026-2031) & (K Units)
Table 63. Americas NSAIDs for Dysmenorrhea Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 64. APAC NSAIDs for Dysmenorrhea SalesForecast by Region (2026-2031) & (K Units)
Table 65. APAC NSAIDs for Dysmenorrhea Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 66. Europe NSAIDs for Dysmenorrhea SalesForecast by Country (2026-2031) & (K Units)
Table 67. Europe NSAIDs for Dysmenorrhea RevenueForecast by Country (2026-2031) & ($ millions)
Table 68. Middle East & Africa NSAIDs for Dysmenorrhea SalesForecast by Country (2026-2031) & (K Units)
Table 69. Middle East & Africa NSAIDs for Dysmenorrhea RevenueForecast by Country (2026-2031) & ($ millions)
Table 70. Global NSAIDs for Dysmenorrhea SalesForecast byType (2026-2031) & (K Units)
Table 71. Global NSAIDs for Dysmenorrhea RevenueForecast byType (2026-2031) & ($ millions)
Table 72. Global NSAIDs for Dysmenorrhea SalesForecast by Application (2026-2031) & (K Units)
Table 73. Global NSAIDs for Dysmenorrhea RevenueForecast by Application (2026-2031) & ($ millions)
Table 74. IOLCP Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 75. IOLCP NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 76. IOLCP NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 77. IOLCP Main Business
Table 78. IOLCP Latest Developments
Table 79. Granules Biocause Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 80. Granules Biocause NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 81. Granules Biocause NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 82. Granules Biocause Main Business
Table 83. Granules Biocause Latest Developments
Table 84. Strides Shasun Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 85. Strides Shasun NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 86. Strides Shasun NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 87. Strides Shasun Main Business
Table 88. Strides Shasun Latest Developments
Table 89. BASF Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 90. BASF NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 91. BASF NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 92. BASF Main Business
Table 93. BASF Latest Developments
Table 94. SI Group Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 95. SI Group NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 96. SI Group NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 97. SI Group Main Business
Table 98. SI Group Latest Developments
Table 99. Hisoar Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 100. Hisoar NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 101. Hisoar NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 102. Hisoar Main Business
Table 103. Hisoar Latest Developments
Table 104. Pfizer Inc Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 105. Pfizer Inc NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 106. Pfizer Inc NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 107. Pfizer Inc Main Business
Table 108. Pfizer Inc Latest Developments
Table 109.Teva Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 110.Teva NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 111.Teva NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 112.Teva Main Business
Table 113.Teva Latest Developments
Table 114. Mylan Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 115. Mylan NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 116. Mylan NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 117. Mylan Main Business
Table 118. Mylan Latest Developments
Table 119. Apotex Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 120. Apotex NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 121. Apotex NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 122. Apotex Main Business
Table 123. Apotex Latest Developments
Table 124. Lupin Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 125. Lupin NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 126. Lupin NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 127. Lupin Main Business
Table 128. Lupin Latest Developments
Table 129. SANOFI-Aventis Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 130. SANOFI-Aventis NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 131. SANOFI-Aventis NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 132. SANOFI-Aventis Main Business
Table 133. SANOFI-Aventis Latest Developments
Table 134. Boehringer-Ingelheim Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 135. Boehringer-Ingelheim NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 136. Boehringer-Ingelheim NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 137. Boehringer-Ingelheim Main Business
Table 138. Boehringer-Ingelheim Latest Developments
Table 139. BEC Chemicals Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 140. BEC Chemicals NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 141. BEC Chemicals NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 142. BEC Chemicals Main Business
Table 143. BEC Chemicals Latest Developments
Table 144. Shandong Xinhua Pharmaceutical Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 145. Shandong Xinhua Pharmaceutical NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 146. Shandong Xinhua Pharmaceutical NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 147. Shandong Xinhua Pharmaceutical Main Business
Table 148. Shandong Xinhua Pharmaceutical Latest Developments
Table 149. Hengrui Medicine Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 150. Hengrui Medicine NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 151. Hengrui Medicine NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 152. Hengrui Medicine Main Business
Table 153. Hengrui Medicine Latest Developments
Table 154. Hubei Biocause Heilen Pharmaceutical Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 155. Hubei Biocause Heilen Pharmaceutical NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 156. Hubei Biocause Heilen Pharmaceutical NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 157. Hubei Biocause Heilen Pharmaceutical Main Business
Table 158. Hubei Biocause Heilen Pharmaceutical Latest Developments
Table 159. Zibo Xinhua-PERRIGO Pharmaceutical Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 160. Zibo Xinhua-PERRIGO Pharmaceutical NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 161. Zibo Xinhua-PERRIGO Pharmaceutical NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 162. Zibo Xinhua-PERRIGO Pharmaceutical Main Business
Table 163. Zibo Xinhua-PERRIGO Pharmaceutical Latest Developments
Table 164. Zhejiang Jiuzhou Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 165. Zhejiang Jiuzhou NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 166. Zhejiang Jiuzhou NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 167. Zhejiang Jiuzhou Main Business
Table 168. Zhejiang Jiuzhou Latest Developments
Table 169. Hubei Xunda Basic Information, NSAIDs for Dysmenorrhea Manufacturing Base, Sales Area and Its Competitors
Table 170. Hubei Xunda NSAIDs for Dysmenorrhea Product Portfolios and Specifications
Table 171. Hubei Xunda NSAIDs for Dysmenorrhea Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 172. Hubei Xunda Main Business
Table 173. Hubei Xunda Latest Developments
LIST OFFIGURES
Figure 1. Picture of NSAIDs for Dysmenorrhea
Figure 2. NSAIDs for Dysmenorrhea Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global NSAIDs for Dysmenorrhea Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global NSAIDs for Dysmenorrhea Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. NSAIDs for Dysmenorrhea Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. NSAIDs for Dysmenorrhea Sales Market Share by Country/Region (2024)
Figure 10. NSAIDs for Dysmenorrhea Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Ibuprofen
Figure 12. Product Picture of Celecoxib
Figure 13. Product Picture of Ketoprofen
Figure 14. Product Picture of Others
Figure 15. Global NSAIDs for Dysmenorrhea Sales Market Share byType in 2025
Figure 16. Global NSAIDs for Dysmenorrhea Revenue Market Share byType (2020-2025)
Figure 17. NSAIDs for Dysmenorrhea Consumed in Hospital
Figure 18. Global NSAIDs for Dysmenorrhea Market: Hospital (2020-2025) & (K Units)
Figure 19. NSAIDs for Dysmenorrhea Consumed in Clinic
Figure 20. Global NSAIDs for Dysmenorrhea Market: Clinic (2020-2025) & (K Units)
Figure 21. NSAIDs for Dysmenorrhea Consumed in Pharmacy
Figure 22. Global NSAIDs for Dysmenorrhea Market: Pharmacy (2020-2025) & (K Units)
Figure 23. NSAIDs for Dysmenorrhea Consumed in Other
Figure 24. Global NSAIDs for Dysmenorrhea Market: Other (2020-2025) & (K Units)
Figure 25. Global NSAIDs for Dysmenorrhea Sale Market Share by Application (2024)
Figure 26. Global NSAIDs for Dysmenorrhea Revenue Market Share by Application in 2025
Figure 27. NSAIDs for Dysmenorrhea Sales by Company in 2025 (K Units)
Figure 28. Global NSAIDs for Dysmenorrhea Sales Market Share by Company in 2025
Figure 29. NSAIDs for Dysmenorrhea Revenue by Company in 2025 ($ millions)
Figure 30. Global NSAIDs for Dysmenorrhea Revenue Market Share by Company in 2025
Figure 31. Global NSAIDs for Dysmenorrhea Sales Market Share by Geographic Region (2020-2025)
Figure 32. Global NSAIDs for Dysmenorrhea Revenue Market Share by Geographic Region in 2025
Figure 33. Americas NSAIDs for Dysmenorrhea Sales 2020-2025 (K Units)
Figure 34. Americas NSAIDs for Dysmenorrhea Revenue 2020-2025 ($ millions)
Figure 35. APAC NSAIDs for Dysmenorrhea Sales 2020-2025 (K Units)
Figure 36. APAC NSAIDs for Dysmenorrhea Revenue 2020-2025 ($ millions)
Figure 37. Europe NSAIDs for Dysmenorrhea Sales 2020-2025 (K Units)
Figure 38. Europe NSAIDs for Dysmenorrhea Revenue 2020-2025 ($ millions)
Figure 39. Middle East & Africa NSAIDs for Dysmenorrhea Sales 2020-2025 (K Units)
Figure 40. Middle East & Africa NSAIDs for Dysmenorrhea Revenue 2020-2025 ($ millions)
Figure 41. Americas NSAIDs for Dysmenorrhea Sales Market Share by Country in 2025
Figure 42. Americas NSAIDs for Dysmenorrhea Revenue Market Share by Country (2020-2025)
Figure 43. Americas NSAIDs for Dysmenorrhea Sales Market Share byType (2020-2025)
Figure 44. Americas NSAIDs for Dysmenorrhea Sales Market Share by Application (2020-2025)
Figure 45. United States NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 46. Canada NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 47. Mexico NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 48. Brazil NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 49. APAC NSAIDs for Dysmenorrhea Sales Market Share by Region in 2025
Figure 50. APAC NSAIDs for Dysmenorrhea Revenue Market Share by Region (2020-2025)
Figure 51. APAC NSAIDs for Dysmenorrhea Sales Market Share byType (2020-2025)
Figure 52. APAC NSAIDs for Dysmenorrhea Sales Market Share by Application (2020-2025)
Figure 53. China NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 54. Japan NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 55. South Korea NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 56. Southeast Asia NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 57. India NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 58. Australia NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 59. ChinaTaiwan NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 60. Europe NSAIDs for Dysmenorrhea Sales Market Share by Country in 2025
Figure 61. Europe NSAIDs for Dysmenorrhea Revenue Market Share by Country (2020-2025)
Figure 62. Europe NSAIDs for Dysmenorrhea Sales Market Share byType (2020-2025)
Figure 63. Europe NSAIDs for Dysmenorrhea Sales Market Share by Application (2020-2025)
Figure 64. Germany NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 65.France NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 66. UK NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 67. Italy NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 68. Russia NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 69. Middle East & Africa NSAIDs for Dysmenorrhea Sales Market Share by Country (2020-2025)
Figure 70. Middle East & Africa NSAIDs for Dysmenorrhea Sales Market Share byType (2020-2025)
Figure 71. Middle East & Africa NSAIDs for Dysmenorrhea Sales Market Share by Application (2020-2025)
Figure 72. Egypt NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 73. South Africa NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 74. Israel NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 75.Turkey NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 76. GCC Countries NSAIDs for Dysmenorrhea Revenue Growth 2020-2025 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of NSAIDs for Dysmenorrhea in 2025
Figure 78. Manufacturing Process Analysis of NSAIDs for Dysmenorrhea
Figure 79. Industry Chain Structure of NSAIDs for Dysmenorrhea
Figure 80. Channels of Distribution
Figure 81. Global NSAIDs for Dysmenorrhea Sales MarketForecast by Region (2026-2031)
Figure 82. Global NSAIDs for Dysmenorrhea Revenue Market ShareForecast by Region (2026-2031)
Figure 83. Global NSAIDs for Dysmenorrhea Sales Market ShareForecast byType (2026-2031)
Figure 84. Global NSAIDs for Dysmenorrhea Revenue Market ShareForecast byType (2026-2031)
Figure 85. Global NSAIDs for Dysmenorrhea Sales Market ShareForecast by Application (2026-2031)
Figure 86. Global NSAIDs for Dysmenorrhea Revenue Market ShareForecast by Application (2026-2031)
More Publications
Global Bench-top Automated Immunoassay Analyzer Market Growth 2025-2031
US$ 3,660.00
March 2025
109 pages
Global Overactive Bladder Therapeutics Market Growth (Status and Outlook) 2024-2030
US$ 3,660.00
August 2024
92 pages
Global Gene Expression Profiling Analysis Market Growth (Status and Outlook) 2024-2030
US$ 3,660.00
March 2024
86 pages
Global Fetal & Neonatal Monitoring Market Growth 2024-2030
US$ 3,660.00
March 2024
115 pages
Global Recombinant Factor VIII Market Growth 2024-2030
US$ 3,660.00
March 2024
101 pages
